Fluidigm to Participate in the 23rd Annual Piper Jaffray Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Fluidigm Corporation (NASDAQ:FLDM) today announced that President and Chief Executive Officer Gajus Worthington will participate in the 23rd Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2011, at the New York Palace Hotel, New York City, beginning at 3:00 p.m. Eastern Time.

Mr. Worthington will provide brief remarks and then the session will transition to a question-and-answer period with the audience, moderated by a Piper Jaffray research analyst.

Audio of the Fluidigm presentation will be simultaneously webcast at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=FLDM&item_id=4229194.

The webcast will be archived for 90 days following the live presentation at http://investors.fluidigm.com/events.cfm.

About Fluidigm

Fluidigm (NASDAQ: FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits, or chips, and reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems including nine different commercial chips to leading pharmaceutical and biotechnology companies, academic institutions and Ag-Bio companies.

For more information, please visit www.fluidigm.com.

“Fluidigm” and the Fluidigm logo are trademarks or registered trademarks of Fluidigm Corporation.



CONTACT:

Fluidigm Corporation
Howard High, 650-266-6081
510-786-7378 (mobile)
[email protected]

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Natural Resources  Agriculture  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.